Week in Review: China is Asia’s Biggest Biotech Cluster

China is Asia’s number one biopharma cluster, according to Genetic Engineering & Biotechnology News, leading other countries in R&D spending, number of life science companies, industry jobs and venture capital investment; the 2014 edition of the ChinaBio Partnering Forum, China’s largest life science partnering event, will take place May 7–8 in Suzhou; the WuXi PharmaTech Healthcare Fund invested in TruTag Technologies, which has developed small, edible microtags to authenticate food and drugs; AstraZeneca will collaborate with Shenzhen University Health Science Center to discover new treatments for chronic kidney disease; the Global Fund met with China drug companies in Shanghai to establish AIDS, TB and malaria treatment supply partnerships; Lansen Pharma paid $8 million upfront to acquire China rights for a Novartis drug that treats inflammatory skin diseases; Morgan Stanley Private Equity Asia continued to take profits from its very successful investment in Sihuan Pharma; and Bayer HealthCare will invest $138 million to expand its Beijing manufacturing facility. More details…. Stock Symbols: (NYSE: WX) (NYSE: AZN) (HK: 503) (NYSE: NVS) (HK: 0460) (XETRA: BAYN) Share this with colleagues: // //